GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Healthequity HQY · USD

Health Care · US listing · 🇺🇸 United States

Compare

102.11

-1.47%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2026

Revenue

$1.31bn

FY2017FY2026

Net income

$215.2m

FY2017FY2026

Free cash flow

$455.1m

FY2017FY2026

Shareholders' equity

$2.11bn

FY2017FY2026

Income statement

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue$1.31bn$1.20bn$999.6m$861.7m$756.6m$733.6m$532.0m$287.2m$229.5m$178.4m
Research and development$262.5m$239.5m$218.8m$193.4m$157.4m$124.8m$77.6m$35.1m$27.4m$22.4m
Operating income$322.5m$230.1m$129.3m$37.7m$40.6m$80.0m$62.0m$77.7m$54.4m$41.2m
Net income$215.2m$96.7m$55.7m−$26.1m−$44.3m$8.8m$39.7m$73.9m$47.4m$26.4m
Diluted earnings per share2.561.110.63-0.30-0.520.110.511.050.740.43

Balance sheet

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assets$3.43bn$3.45bn$3.16bn$3.09bn$3.11bn$2.71bn$2.56bn$510.0m$369.2m$279.1m
Cash and short-term investments$318.9m$295.9m$404.0m$254.3m$225.4m$328.8m$191.7m$361.5m$240.3m$180.4m
Total liabilities$1.32bn$1.33bn$1.13bn$1.19bn$1.25bn$1.33bn$1.53bn$32.9m$22.9m$17.2m
Debt$967.3m$1.06bn$875.0m$925.3m$930.8m$986.7m$1.22bn———
Shareholders' equity$2.11bn$2.11bn$2.04bn$1.90bn$1.85bn$1.38bn$1.03bn$477.1m$346.3m$261.9m
Shares outstanding84m87m89m87m85m84m78m71m64m62m

Cash flow

Fiscal years

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations$457.1m$339.9m$242.8m$150.7m$141.0m$181.6m$105.9m$113.4m$81.7m$45.6m
Capital spending−$2.0m−$2.1m−$46.1m−$119.1m−$137.1m−$97.0m−$42.1m−$15.0m−$33.4m−$12.7m
Free cash flow$455.1m$337.8m$196.8m$31.5m$3.9m$84.7m$63.8m$98.4m$48.3m$32.9m

Latest quarters

By quarter end

Jul 2026Apr 2026Jan 2026Oct 2025Jul 2025Apr 2025Jan 2025Oct 2024
Revenue$350.7m$354.6m$334.6m$322.2m$325.8m$330.8m$311.8m$300.4m
Operating income$98.7m$113.7m$67.4m$79.9m$90.9m$84.4m$71.5m$20.5m
Net income$65.6m$69.4m$49.7m$51.7m$59.9m$53.9m$26.4m$5.7m
Diluted earnings per share0.780.830.590.590.690.620.300.06
Cash from operations$136.0m$97.0m$117.0m$138.0m$135.0m$64.0m$75.0m$90.0m
Capital spending——−$16.0m—−$15.0m−$16.0m−$13.0m−$12.0m
Free cash flow——$101.0m—$120.0m$48.0m$62.0m$78.0m
Total assets$3.27bn$3.31bn$3.43bn$3.40bn$3.42bn$3.42bn$3.45bn$3.49bn
Cash and short-term investments$256.0m$265.4m$318.9m$309.3m$304.5m$287.9m$295.9m$322.2m
Debt$941.0m$952.6m$967.3m$992.0m$1.02bn$1.07bn$1.07bn$1.10bn
Shareholders' equity$1.99bn$2.05bn$2.11bn$2.13bn$2.15bn$2.12bn$2.11bn$2.12bn

Financial ratios

Data as of 12 Oct 2026

FY2026FY2025FY2024FY2023FY2022FY2021
Operating margin25.5%14.6%12.9%1.2%-4.5%5.3%
Net margin16.4%8.1%5.6%-3.0%-5.9%1.2%
Return on equity10.2%4.6%2.7%-1.4%-2.4%0.6%
Return on assets6.3%2.8%1.8%-0.8%-1.4%0.3%
Free cash flow yield5.9%4.2%3.5%3.3%3.6%3.6%
Revenue growth9.5%20.0%16.0%13.9%3.1%37.9%
Earnings growth122.5%73.6%-313.1%-41.0%-601.3%-77.7%
Current ratio3.27x3.06x4.76x2.92x2.29x2.25x
Debt to equity0.46x0.50x0.43x0.49x0.51x0.73x
Equity ratio61.4%61.3%64.3%61.4%59.6%50.9%
Interest coverage5.86x2.89x2.33x0.21x-0.94x1.12x
R&D as a share of sales20.0%20.0%21.9%22.4%20.8%17.0%
Buybacks as a share of market value3.4%1.9%-1.7%-3.0%-1.2%-7.3%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue15.1%12.4%26.3%
Operating income104.6%32.2%28.6%
Net income—89.4%29.2%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin22.0%16.4%14.3%15.3%
Net margin12.4%7.8%5.2%7.1%

Valuation history

At each fiscal year end

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings42.582.4152.7-220.9-117.7418.4136.870.780.5109.5
Price to sales7.06.68.56.76.95.010.218.216.616.2

Market value over time

30 Nov 2016 to 9 Oct 2026, in USD

$2.67bn$7.78bn

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return4%43%4%57%-41%-10%25%21%20%61%

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.